SSY Group's H1 2025 revenue and profit fall significantly

For the six months ended June 30, 2025, SSY Group reported revenue of HK$2,147m, a 36% decrease from HK$3,338m in the corresponding period last year. Net profit also fell significantly by 58.7% to HK$284m, down from HK$685m previously. This downturn was primarily attributed to a 37% decline in intravenous infusion solution sales volume and a 45% reduction in related revenue to HK$1,199m, coupled with a 57% decrease in ampoule injection revenue to HK$157m.

Despite these challenges, the group's oral preparations business saw a 16% increase in revenue to HK$296m, driven by new product sales and renewed centralized procurement agreements. Medical materials sales also rose by 7.1% to HK$101m. The board declared an interim dividend of HK$0.05 per share, a 37.5% decrease from HK$0.08 per share in the prior year.

The company is focusing on innovation, market access, and cost control to navigate the difficult economic landscape. As of June 30, 2025, the group's cash and cash equivalents increased by 6.4% to HK$1,338m, while bank borrowings rose by 10.4% to HK$4,015m.